RecruitingNCT04262492
International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants
OBServaToire INternational Des Patients AnTiphospholipidEs traités Par Anticoagulants Oraux Directs
Sponsor
Stéphane Zuily
Enrollment
500 participants
Start Date
Oct 21, 2020
Study Type
OBSERVATIONAL
Conditions
Summary
This registry, currently being established will ensure consistency of data collection and provide safety information in non high-risk APS patients currently on DOACs.
Eligibility
Inclusion Criteria4
- Patient receiving a comprehensive information about the study, and not opposed to participate
- Age ≥ 18 yo
- Classification of definite APS according to revised Sapporo-Sydney criteria
- Direct oral anticoagulant treatment prescribed during at least 6 months or with the possibility of follow-up of at least 6 months
Exclusion Criteria4
- Incomplete revised Sapporo-Sydney criteria
- No data regarding the recurrent thrombosis
- Pregnant woman
- Age < 18 yo
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGRivaroxaban
Rivaroxaban 10 mg or 15 mg or 20 mg OD Dabigatran 110 mg or 150 mg BID Apixaban 2.5 mg or 5 mg or 10 mg BID
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04262492
Related Trials
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
NCT0019806810 locations
ATHNdataset Registry
NCT068205151 location
Platelet Volunteers, Longitudinal and Multi-omic Study
NCT071374291 location
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
NCT070879122 locations
Multi-Omics-Based Novel Thrombosis and Bleeding Markers and Risk Model for CHD
NCT075238803 locations